Breaking Finance News

Novavax (NASDAQ:NVAX) target price reduced to $12.00, reported today by FBR & Co.

Reporting a possible upside of 0.44%, FBR & Co. lowered the target price of Novavax (NASDAQ:NVAX) to $12.

On 8/23/2016, Vetr Inc. reported on Novavax(NASDAQ:NVAX) bumped the target price from $0.00 to $8.66. At the time, this suggested an upside of 0.17%.

Only yesterday Novavax (NASDAQ:NVAX) traded 0.36% higher at $8.34. Novavax’s 50-day average is $7.35 and its 200-day average is $6.24. The last stock price close is up 33.70% from the 200-day moving average, compared to the S&P 500 Index which has fallen -0.01% over the same time. 25,965,663 shares of Novavax traded, up from ann average volume of 5,016,980.

Recent Performance Graph:


Novavax has a one-year low of $4.08 and a one-year high of $10.70. NVAX’s market cap is currently $0.0.

A total of 8 brokerages have released a ratings update on the company. Five analysts rate the company a strong buy, three firms rate the company a buy, 0 analysts rate the stock a hold, 0 rate the company to underperform, and lastly 0 brokeragesrate the stock as sell with a one year target of $15.39

Brief Synopsis About Novavax (NASDAQ:NVAX)

Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, and including Middle East respiratory syndrome (MERS).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *